LLY Jan 2025 310.000 put
| Previous Close | 5.50 |
| Open | 5.50 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 310.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 5.50 - 5.50 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 174 |
Yahoo FinanceAmazon Health: A long play and a search for partners
Amazon Pharmacy is just one of the segments of health that the e-retail giant is pursuing.
- Reuters
INSIGHT-Wegovy, other weight-loss drugs scrutinized over reports of suicidal thoughts
“I knew it was the drug,” said Heidlebaugh, who said she had not previously suffered from depression. Heidlebaugh is one of four U.S. patients who told Reuters about experiencing suicidal thoughts while taking Novo Nordisk’s popular Ozempic drug, approved to treat type 2 diabetes, or Wegovy, another Novo top-seller approved for weight loss. A fifth patient said he experienced depression and suicidal thoughts after taking Mounjaro, a similar diabetes medicine from Eli Lilly, which is also used for weight loss.
ReutersUS judge overturns Eli Lilly's $176.5 million loss in Teva patent case
Drugmaker Eli Lilly convinced a federal judge in Massachusetts on Tuesday to overturn a $176.5 million jury verdict for Teva Pharmaceutical that found Lilly's migraine drug Emgality infringed three patents related to Teva's rival drug Ajovy. U.S. District Judge Allison Burroughs said in a post-trial ruling that the Teva patents covering the use of antibodies to inhibit headache-causing peptides were invalid. "The Court does not reach this decision nor overturn a jury verdict lightly," Burroughs said.
